Rentokil Initial (RTO) analyst forecast and price target
Analyst forecast
Consensus of 20 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Goldman Sachs | Upgraded | Neutral → Buy | — | Jul 7, 2026 |
| UBS | Upgraded | Neutral → Buy | — | Mar 12, 2026 |
| Oppenheimer | Maintained | Outperform | $35.00 from $30.00 | Mar 10, 2026 |
| JP Morgan | Maintained | Overweight | — | Nov 21, 2025 |
| Bernstein | Upgraded | Underperform → Outperform | — | Oct 7, 2025 |
| Redburn Atlantic | Downgraded | Buy → Neutral | — | Sep 19, 2024 |
| UBS | Upgraded | Sell → Neutral | — | Jul 1, 2024 |
| Exane BNP Paribas | Upgraded | Neutral → Outperform | — | Mar 18, 2024 |
| B of A Securities | Downgraded | Buy → Neutral | $29.00 from $40.00 | Jan 24, 2024 |
| Oppenheimer | Maintained | Outperform | $47.00 from $40.00 | May 22, 2023 |
Frequently asked questions
Is RTO a buy, sell, or hold?
Analysts covering Rentokil Initial currently average a Buy rating: 13 buy, 7 hold and 0 sell, from 20 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on RTO?
On Jul 7, 2026, Goldman Sachs upgraded Rentokil Initial to Buy.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.